ANAVASI DIAGNOSTICS ANNOUNCES NEWLY ELECTED OUTSIDE BOARD OF DIRECTORS
Retrieved on:
Wednesday, November 2, 2022
Marketing, RNA, Growth, Board of directors, CEO, Procter & Gamble, BBC, Doctor of Philosophy, Vector Security, General manager, Korn Ferry, Research, Board, BPS, Acceleration, NIH, Microalgae, Nasdaq, Industry, Medical device, Baxter, Health, Baxter International, Portable ultrasound, Microsoft, Technology, National, Drexel Burnham Lambert, Pulmonary hypertension, Compliance, Company, Noble gas, Severe acute respiratory syndrome coronavirus 2, Global, Pharmaceutical industry, Management, UW, Illumina
WOODINVILLE, Wash., Nov. 2, 2022 /PRNewswire/ -- Anavasi Diagnostics ('Anavasi'), an NIH/RADx medical technology company focused on the development of novel molecular diagnostic testing, recently announced the election of three new outside members to its Board of Directors, Bryan Crane, PhD, Arthur Kirsch, and David Vied.
Key Points:
- WOODINVILLE, Wash., Nov. 2, 2022 /PRNewswire/ -- Anavasi Diagnostics ('Anavasi'), an NIH/RADx medical technology company focused on the development of novel molecular diagnostic testing, recently announced the election of three new outside members to its Board of Directors , Bryan Crane, PhD, Arthur Kirsch, and David Vied.
- "We are thankful to have these three talented individuals join the board,"said Nelson Patterson, President, and CEO of Anavasi Diagnostics.
- Vied join a seasoned executive team of Board of Directors, led bythe President and CEO, Nelson Patterson.
- Anavasi Diagnostics is a rapidly growing medical technology company focused on developing novel molecular diagnostic testing using a proprietary reverse transcriptase methodology (patent-pending).